The competition for developing a possible Coronavirus vaccine is in the rounds for quite some time now as the Covid-19 cases across the world has exceeded 4 million mark in infection and caused the death of six lakh people.
In the midst of the infections and recuperations, many countries like India, Russia, US, UK are accelerating their operations to develop a vaccine for the virus. US, China and Europe have all initiated research programs and supply chains for vaccine production.
India’s first indigenous vaccine Covaxin got a go-ahead from the AIIMS Ethics Committee on Saturday to kick-off human trial from Monday. AIIMS Delhi is one of the 12 sites picked by the Indian Council for Medical Research for conducting phase 1 and 2 human trials. In phase one, the vaccine would be put to the test on 375 volunteers and a maximum of 100 of them whould be from AIIMS.
Drug company Zydus Cadila also stated that it has begun human trial of its vaccine contender ZyCoV-D. During the phase of trials, the Drug firm will be registering more than 1000 subjects across several clinical study sites in India, it stated in a regulatory filling.
Russian health minister stated that they will make a Covid-19 vaccine candidate accessible to general public before it finishes the third and last phase of clinical trials.
As maintained by Bloomberg report, Kirill Dmitriev, the chief executive of the Direct Investment Fund (RDIF), stated that the vaccine will begin third phase trials in thousands of people on August. 3 in Russia as well as in Saudi Arabia and the UAE. "Russia could make 30 million doses domestically in 2020, and 170 million abroad, with five countries expressing interest in producing the vaccine and others willing to produce it", he said.
China has set itself to be a strong candidate. The human trial being performed by Chinese firm Sinovac Biotech have arrived at the third state. This is the first vaccine to get to the human trials. The first dosage was carried out on 15,000 registered volunteers in Abu Dabhi. They were provided with the vaccine twice inside 28 days and the researchers witnessed origination of anti bodies in in them. There are four vaccines being developed in China.
Eight out of almost two dozen potential vaccines are in varying phase of human trial worldwide are produced in China, SinoPharm and another Chinese firms have already announced that they're setting foot in final testing.
The vaccine made by Oxford University and Imperial College are in second and third stage of human trials. About 105 people are expected to be given the vaccine. The stage 3 trial is expected to commence in November and will deal with 6,000 people.
Not Long ago, Researchers at the University of Oxford believe that they may leap forward in their pursue of coronavirus vaccine after the team found that the jab could provide "double protection" against the deadly pathogen following early stage human trials, as per media reports in the UK
Blood samples taken from a group of volunteers in UK who were given a dose of the vaccine displayed that it stimulated the body to produce both antibodies and “killer T-cells".
United States biotech company’s vaccine developed antibodies in all patients tested in the begining safety experiment, federal researchers stated. Moderna’s first outcome are from the initial group who was given the vaccine, known as mRNA-1273. It estimated three doses that were given in a two-shot program. The middle one was chosen for use in the large final-stage study that is scheduled to start on 27th July.
Also Read: Maharashtra: Six COVID-19 patients booked for not wearing masks in isolation centre